We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+15.18%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.32B
AUM Growth
+$87.8M
Cap. Flow
+$6.46M
Cap. Flow %
0.49%
Top 10 Hldgs %
27.55%
Holding
138
New
17
Increased
50
Reduced
27
Closed
18

Top Buys

Rank Stock Value
1
BXLT
BAXALTA INC COM STK (DE)
BXLT
+$28.2M
2
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$22.2M
3
WCG
Wellcare Health Plans, Inc.
WCG
+$17.8M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$17.5M
5
AGN
Allergan plc
AGN
+$10.7M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$38M
2
STJ
St Jude Medical
STJ
+$33.4M
3
TMH
Team Health Holdings Inc
TMH
+$17M
4
ADPT
Adeptus Health Inc
ADPT
+$14.4M
5
TRNX
TORNIER N V SHARES (NLD)
TRNX
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 77%
2 Financials 3.37%
3 Industrials 0.48%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
26
Biogen
BIIB
$30.7B
$15.5M 1.18%
50,650
+12,000
+31% +$3.45M
MCK icon
27
McKesson
MCK
$101B
$14.3M 1.08%
72,500
+2,500
+4% +$472K
TMO icon
28
Thermo Fisher Scientific
TMO
$220B
$14.2M 1.07%
100,000
– –
MD icon
29
Pediatrix Medical
MD
$2.2B
$13.8M 1.05%
193,000
+68,000
+54% +$5.03M
INCY icon
30
Incyte
INCY
$24.4B
$13.8M 1.04%
127,000
+14,000
+12% +$1.56M
LKFT
31
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
$13.2M 1%
210,000
– –
AMGN icon
32
Amgen
AMGN
$222B
$13.1M 1%
80,900
-2,350
-3% -$369K
TVTX icon
33
Travere Therapeutics
TVTX
$5.78B
$13M 0.99%
675,000
-8,900
-1% -$178K
ARDX icon
34
Ardelyx
ARDX
$997M
$12.4M 0.94%
682,500
+1,000
+0.1% +$18.6K
TXMD icon
35
TherapeuticsMD
TXMD
$24M
$12.3M 0.93%
23,700
+8,200
+53% +$3.03M
ACHN
36
DELISTED
Achillion Pharmaceuticals
ACHN
$11.9M 0.9%
1,105,000
-20,000
-2% -$182K
RARE icon
37
Ultragenyx Pharmaceutical
RARE
$2.55B
$11.8M 0.9%
105,500
-1,500
-1% -$150K
KDNY
38
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$11.7M 0.88%
83,000
– –
PRAH
39
DELISTED
PRA Health Sciences, Inc.
PRAH
$11.5M 0.87%
253,000
– –
JAZZ icon
40
Jazz Pharmaceuticals
JAZZ
$16.7B
$11.3M 0.86%
80,300
+28,800
+56% +$3.99M
PEN icon
41
Penumbra
PEN
$12.8B
$11M 0.84%
205,000
+10,000
+5% +$453K
WMGI
42
DELISTED
Wright Medical Group Inc
WMGI
$11M 0.84%
+456,000
New +$9.88M
TBPH icon
43
Theravance Biopharma
TBPH
$877M
$10.6M 0.8%
645,000
+42,500
+7% +$674K
DERM
44
DELISTED
Dermira, Inc.
DERM
$10M 0.76%
290,000
-10,001
-3% -$287K
INSY
45
DELISTED
Insys Therapeutics, Inc.
INSY
$9.69M 0.73%
338,500
+30,500
+10% +$845K
ITCI
46
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$9.68M 0.73%
180,000
– –
CORV
47
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$9.65M 0.73%
1,190,000
– –
CHMA
48
DELISTED
Chiasma, Inc. Common Stock
CHMA
$9.54M 0.72%
487,500
-35,000
-7% -$758K
IDXX icon
49
Idexx Laboratories
IDXX
$46.2B
$9.3M 0.7%
127,500
+15,000
+13% +$1.07M
ADAP
50
DELISTED
Adaptimmune Therapeutics
ADAP
$9.23M 0.7%
765,001
+8,901
+1% +$87.2K
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2015 Portfolio in Review

As of Q4 2015, Rock Springs Capital Management held 138 positions worth $1.32B, up 7.1% from $1.23B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Rock Springs Capital Management's Q4 2015 filing shows 17 new, 50 increased, 27 reduced and 18 closed positions. Its largest new stake was BAXALTA INC COM STK (DE): 810,000 shares worth $31.6M. The largest sale was AbbVie, an estimated $38M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 76% a quarter earlier, followed by Financials and Industrials.

  • Rock Springs Capital Management's largest Q4 2015 buy was BAXALTA INC COM STK (DE): 810,000 shares worth $31.6M.
  • Rock Springs Capital Management added most to Allergan plc in Q4 2015, an estimated $10.7M increase.
  • Rock Springs Capital Management's biggest Q4 2015 reduction was AbbVie, cutting an estimated $38M.
  • Rock Springs Capital Management fully exited St Jude Medical in Q4 2015, selling an estimated $33.4M.
  • Rock Springs Capital Management's ten largest holdings make up 28% of its $1.32B portfolio in Q4 2015.
  • Rock Springs Capital Management opened 17 new positions and closed 18 in Q4 2015.
  • Rock Springs Capital Management's portfolio value rose 7.1% quarter-over-quarter to $1.32B.

Based on Rock Springs Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.